News
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
Why Vertex Stock Is Soaring Today
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage
Why Pfizer Stock Is Sinking Today
Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.
Pfizer expects 2024
1 Biotech Stock That Could Be the Next Amgen
The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the
2 Big-Name Stocks Are Falling Wednesday -- Here's Why
The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting
If You Had Invested $100 in AT&T in 1995, This Is How Much You Would Have Today
Telecommunications giant AT&T (NYSE: T) is a household name and a well-known dividend stock. Had you invested $100 in AT&T in 1995, your investment would have grown to $476 today. Is that good
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive
2 Artificial Intelligence Stocks to Buy Hand Over Fist in 2024
For the past few years, Wall Street has witnessed several hot investment trends -- be it cannabis, the metaverse, cryptocurrency, blockchain, cloud computing, and now artificial intelligence (AI)
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the
Is AT&T a Buy?
Telecom giant AT&T (NYSE: T) gets talked about often in the investing world, but it isn't typically positive. Despite having a commanding market share (47% of U.S. wireless subscriptions in the
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes
3 Dirt Cheap Stocks That Make Terrific Buys Before the End of the Year
The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks
EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
Valbiotis announces the launch of a capital increase
Valbiotis announces the availability of an amendment to the Universal Registration Document
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge
What AT&T Investors Need to Know About the $14 Billion Open RAN Deal
Telecom giant AT&T (NYSE: T) is embarking on a revamp of its wireless network infrastructure. The company announced last week that it had signed a deal with Sweden's Ericsson to spend as much as $14
Is Now the Right Time to Buy AstraZeneca Stock?
With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's
3 Unstoppable Stocks to Buy Right Now
What are some unstoppable stocks to buy right now? Three Fool.com contributors think they've found three stocks that qualify -- and they're all in the healthcare sector. Here's why they picked